Argus reiterated its "buy" rating for Plainsboro, N.J.-based Integra LifeSciences, according to Yahoo! Finance. Argus offers independent research, as opposed to sell-side research.
Here are six takeaways:
1. The analyst firm also gave the company a $58 post-split target price, which is $3 higher than the highest target price on Wall Street.
2. Ultimately, Argus gave Integra a nearly 40 percent upside.
3. The analyst noted the company's strong growth potential as well as ability to act on acquisition and merger moves.
4. Integra acquired Derma Sciences in March, and made a binding offer to acquire Johnson & Johnson Codman Neurosurgery in the first quarter of 2017. Argus predicted these acquisitions could result in an additional $400 million in annual sales.
5. Argus also kept a close eye on Integra's product launches in the first quarter of this year, including a neurosurgery tissue ablation system and a reverse-shoulder implant.
6. The firm pointed to tissue regeneration products and neurosurgery instruments as driving product lines for Integra.